Clinical trials: Pulmonary Artery Hypertension
Systemic Sclerosis, Pulmonary Arterial Hypertension
Extracellular Vesicle Dynamics Predicting Vascular Complications and Treatment Response in Systemic Sclerosis
Systemic sclerosis is a multisystem autoimmune disease characterized by vascular dysfunction, immune dysregulation, and progressive tissue fibrosis.
- Conditions
- Systemic Sclerosis, Pulmonary Arterial Hypertension, Digital Ulcers, Vascular Complications
- Trial name
- EVOLVE-SSc (NCT07717060)
- Testing
- Blood sampling, nailfold capillaroscopy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Pulmonary Arterial Hypertension, Obstructive Sleep Apnea
Obstructive Sleep Apnea (OSA) in Pulmonary Arterial Hypertension (PAH)
The purpose of this study is to determine whether pulmonary arterial hypertension can worsen or even cause sleep apnea. It is hypothesized that if pulmonary arterial hypertension does indeed worsen or cause sleep apnea, then the…
- Trial name
- NCT01835080
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Inova Health Care Services
Hypertension, Pulmonary
The Exercise Capacity and Quality of Life in the Patients With IPAH and Secondary PH
Pulmonary hypertension (PH) is a progressive disease with high mortality rate, but due to the development of drugs, the prognosis of the disease has improved.
- Trial name
- NCT02647060
- Where
- Taiwan
- Volunteers
- 26 people
- Sponsor
- National Taiwan University Hospital
Pulmonary Arterial Hypertension
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
The purpose of this study is: To investigate CYP2C9 inhibition by BIA 5-1058 through the assessment of its effect on the Pharmacokinetic (PK) of S-warfarin, a substrate of CYP2C9.
- Trial name
- NCT04994119
- Testing
- BIA 5-1058, Warfarin
- Where
- Germany
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Atrial Septal Defects, Ventricular Septal Defects
Evaluation of Latent Pulmonary Arterial Hypertension in Congenital Shunt Lesions
Prospective, monocentric study for the evaluation of latent pulmonary arterial hypertension in patients with congenital shunt lesions lost to follow-up. Lost to follow-up is defined as latest clinical control ≥ 5 years.
- Trial name
- NCT02552485
- Testing
- No intervention was applied, because it is an observational study
- Where
- Belgium
- Volunteers
- 93 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pulmonary Hypertension
Effect of Normobaric Hypoxia and Hyperoxia in Patients With Pulmonary Hypertension
Pulmonary Hypertension (PH) is a severe disease with a bad prognosis. However, thanks to extensive research in this field, there are more and better treatment options that allow patients to participate in recreational activities…
- Trial name
- NCT03195959
- Testing
- Hypoxia and Hyperoxia
- Where
- Switzerland
- Volunteers
- 44 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease
An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The purpose of this study is to provide continued access to TPIP for participants who have successfully completed the open-label extension (OLE) studies of INS1009-203 for PAH or INS1009-212 for PH-ILD.
- Trial name
- NCT06939647
- Testing
- Treprostinil Palmitil
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Positioning Imatinib for Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a rare condition in which a narrowing of blood vessels carrying blood through the lungs puts an increased work load on the heart; it has to work harder to pump blood through the lungs.
- Trial name
- PIPAH (NCT04416750)
- Testing
- Imatinib Mesylate
- Where
- 4 sites in United Kingdom
- Volunteers
- 17 people
- Sponsor
- Imperial College London
Asthma, Coronary Artery Disease
Care Transitions for Complex Patient - Cycle 1 and Cycle 2
The purpose of this study is to improve patient care and safety while decreasing ED visit rates by sending specific information about care transitions related to hospital admission and discharge and emergency department and…
- Conditions
- Asthma, Coronary Artery Disease, Diabetes, Hypertension
- Trial name
- NCT01039324
- Testing
- Reports, Reports and Notices, Usual care
- Where
- United States
- Volunteers
- 8,422 people
- Sponsor
- Duke University
Heart Failure, Diastolic, Pulmonary Hypertension
Sildenafil in HFpEF (Heart Failure With Preserved Ejection Fraction) and PH
Aim of the study is to investigate whether Sildenafil treatment results in a reduction of pulmonary artery pressure without decrease of cardiac output (CO) and in improvement of exercise capacity in patients with heart failure…
- Trial name
- NCT01726049
- Testing
- Sildenafil
- Where
- Netherlands
- Volunteers
- 52 people
- Sponsor
- University Medical Center Groningen
PAH, CTEPH
Effects of Pulmonary Rehabilitation on Quality of Life and Health in Pulmonary Arterial Hypertension Patients
Pulmonary hypertension (PH) is a major global health concern, affecting approximately 1% of the world's population. With global aging and increased life expectancy, its incidence continues to rise.
- Trial name
- EPRQoL-PAH (NCT06973382)
- Testing
- Comprehensive Pulmonary Rehabilitation Program, Standard Pulmonary Rehabilitation
- Volunteers
- 84 people
- Sponsor
- Beijing Chao Yang Hospital
Pulmonary Hypertension
Smoking: a Risk Factor for Pulmonary Arterial Hypertension?
Environmental factors may play a role in the genesis of pulmonary hypertension, especially in endothelial dysfunction. One widespread environmental factor associated with systemic endothelial dysfunction is cigarette smoke.
- Trial name
- DACH (NCT01484899)
- Where
- 9 sites in Austria, Germany and 1 more
- Volunteers
- 500 people
- Sponsor
- University of Zurich
Pulmonary Arterial Hypertension
A Long Term Extension Study Evaluating Safety Of Sildenafil Citrate When Used To Treat Pulmonary Arterial Hypertension (PAH) In Children
Active treatment, dose-blinded extension study evaluating the safety and long term efficacy of sildenafil citrate in children with PAH.
- Trial name
- NCT00159874
- Testing
- Sildenafil citrate
- Where
- 39 sites in United States, Brazil and 13 more
- Volunteers
- 234 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Emergency Department Patients, Pulmonary Hypertension
Pulmonary Artery Pressure in Predicting Pulmonary Embolism in Patients Presenting To The Emergency Department With Dyspnea
The aim of this study is to determine the usability of echocardiographic PAP changes obtained from emergency department records in the early risk stratification of pulmonary embolism.
- Conditions
- Emergency Department Patients, Pulmonary Hypertension, Pulmonary Embolism
- Trial name
- NCT07641400
- Testing
- Pulmonary embolism (+), pulmonary embolism (-)
- Where
- Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Antalya Health Sciences University
Chronic Kidney Disease, Hemodialysis
Effect of Dry-weight Probing Guided by Lung-Ultrasound on Ambulatory Blood Pressure and Arterial Stiffness in Hemodialysis Patients (LUST Sub-Study)
The most common co-morbidity accompanying Chronic Kidney Disease (CKD) is hypertension, which appears in approximately 80% of all patients with renal dysfunction, whereas its prevalence in general population is remarkably lower…
- Conditions
- Chronic Kidney Disease, Hemodialysis, Hypertension
- Trial name
- LUST ABPM (NCT03058874)
- Testing
- Extra-vascular lung water measurements by ultrasound, Standard protocol of fluid management in hemodialysis
- Where
- 2 sites in Greece, Slovenia
- Volunteers
- 71 people
- Sponsor
- Carmine Zoccali
Healthy Volunteer
A Healthy Volunteer Study Evaluating the the Safety, Tolerability, and Pharmacokinetics of RT234
The objective of this two part study was to demonstrate safety, tolerability, and pharmacokinetics of RT234 in healthy volunteers.
- Trial name
- NCT05567367
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI), Vardenafil Oral Tablet
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies
A surveillance of respiratory tract related adverse events in patients treated with Tyvaso®(treprostinil) Inhalation Solution versus other FDA approved therapies
- Trial name
- Aspire (NCT01266265)
- Testing
- inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin
- Where
- 88 sites in United States
- Volunteers
- 1,333 people
- Sponsor
- United Therapeutics
PAH
Safety, Tolerability, and Pharmacokinetics of Oral Treprostinil in Pediatric PAH Patients Aged 7 to 17 Years
This was a multi-center, open-label, safety, tolerability and pharmacokinetic study of oral treprostinil in pediatric subjects with stable PAH aged 7 to 17 years who were (1) transitioning from parenteral Remodulin therapy; (2)…
- Trial name
- NCT02276872
- Testing
- oral treprostinil
- Where
- 9 sites in United States
- Volunteers
- 32 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension
Open-label, Clinical Study to Evaluate the Safety and Tolerability of TreT in Subjects With PAH Currently Using Tyvaso
This was a Phase 1b safety and tolerability single-sequence study in which PAH subjects on a stable regimen of Tyvaso switched to a corresponding dose of TreT.
- Trial name
- BREEZE (NCT03950739)
- Testing
- Treprostinil Inhalation Powder
- Where
- 16 sites in United States
- Volunteers
- 51 people
- Sponsor
- United Therapeutics
Pulmonary Artery Hypertension
Impact of Aerobic Training on Sleep Quality and Aerobic Fitness in Male Patients With Pulmonary Artery Hypertension
This study investigated the effect of 12 weeks of aerobic training on sleep quality and aerobic fitness in patients with Pulmonary arterial hypertension(PAH).
- Trial name
- NCT04337671
- Testing
- Moderate intensity aerobic training
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Cairo University